🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. Amifampridine Phosphate

    CATALYST PHARMACEUTICALS, INC.

    Muscular Atrophy, Spinal

    phase 2 small molecule completed

    1 trial

  2. Amifampridine Phosphate 10 MG Oral Tablet

    CATALYST PHARMACEUTICALS, INC.

    Spinal Muscular Atrophy Type 3

    phase 2 small molecule terminated

    1 trial

  3. Amlitelimab, Amlitelimab matching placebo comprised of the same excipients as the Test product without the active substance

    Sanofi-aventis Healthcare Pty Ltd

    Hidradenitis

    phase 2 small molecule active

    1 trial

  4. Amlitelimab, Amlitelimab matching placebo to test product

    Sanofi-aventis Healthcare Pty Ltd

    Coeliac disease

    phase 2 small molecule active

    1 trial

  5. Amlitelimab, Amlitelimab matching placebo to test product

    Sanofi-aventis Healthcare Pty Ltd

    Alopecia areata

    phase 2 small molecule active

    1 trial

  6. Amlitelimab, Placebo

    Sanofi-aventis Healthcare Pty Ltd

    Asthma

    phase 2 small molecule active

    1 trial

  7. Amyvid 1900 MBq/mL solution for injection, Neuraceq 300 MBq/mL solution for injection, 0.9% (w/v) sodium chloride (Normal Saline), VIZAMYL 400 MBq/mL solution for injection, Amyvid 800 MBq/mL solution for injection

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  8. Amyvid 800 MBq/mL solution for injection, ACU193 matching Placebo, Neuraceq 300 MBq/mL solution for injection, ACU193, VIZAMYL 400 MBq/mL solution for injection

    Acumen Pharmaceuticals

    Early Alzheimer’s Disease (Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease)

    phase 2 small molecule active

    1 trial

  9. Apart from the AP1189 granulate, the placebo tablet and AP1189 tablet are identical., AP1189 Tablet

    Lacuna Pharma Pty Ltd

    Idiopathic membranous nephropathy and severe proteinuria

    phase 2 small molecule active

    1 trial

  10. Apart from the AP1189 granulate, the placebo tablet and AP1189 tablet are identical., AP1189 Tablet

    Lacuna Pharma Pty Ltd

    Polymyalgia rheumatica

    phase 2 small molecule active

    1 trial

  11. Aplindore

    LIGAND PHARMACEUTICALS INC

    Restless Legs Syndrome

    phase 2 small molecule completed

    1 trial

  12. Aplindore

    LIGAND PHARMACEUTICALS INC

    Early Stage Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  13. Aramchol

    Galmed Pharmaceuticals

    Gallstones

    phase 2 small molecule terminated

    1 trial

  14. Aramchol

    Galmed Pharmaceuticals

    Non-Alcoholic Fatty Liver Disease

    phase 2 small molecule completed

    1 trial

  15. Aramchol

    Galmed Pharmaceuticals

    Fatty Liver

    phase 2 small molecule completed

    1 trial

  16. Aramchol meglumine

    Galmed Pharmaceuticals

    Primary Sclerosing Cholangitis

    phase 2 small molecule terminated

    1 trial

  17. Aritinercept

    Aurinia Pharmaceuticals

    Myasthenia Gravis, Generalized

    phase 2 small molecule active

    1 trial

  18. Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation

    Amphastar France Pharmaceuticals

    Asthma

    phase 2 small molecule terminated

    1 trial

  19. Arm T1: Primatene Mist HFA

    Amphastar France Pharmaceuticals

    Asthma

    phase 2 small molecule completed

    1 trial

  20. Arvisol placebo, Arvisol 150mg

    Pari Pharma GmbH

    Patients with severe Alcohol Use Disorder (according to DSM 5) at entry of a scheduled inpatient alcohol cessation attempt

    phase 2 small molecule active

    1 trial

  21. Asciminib, ASCIMINIB HYDROCHLORIDE

    Novartis Pharmaceuticals

    Philadelphia positive Chronic Myeloid leukemia in Chronic Phase with newly diagnosed and resistant/intolerant to previous TKIs, with or without the T315I mutation

    phase 2 small molecule active

    1 trial

  22. Asparaginase Erwinia chrysanthemi

    Jazz Pharmaceuticals Ireland Limited

    B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

    phase 2 small molecule active

    1 trial

  23. Aspirin Challenge

    Regeneron UK Limited

    Aspirin-exacerbated Respiratory Disease

    phase 2 small molecule completed

    1 trial

  24. Atezolizumab

    Syndax Pharmaceuticals

    Metastatic Cancer

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources